Media coverage about Sierra Oncology (NASDAQ:SRRA) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sierra Oncology earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.7765045500986 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Sierra Oncology stock opened at $2.02 on Friday. The firm has a market capitalization of $152.07, a PE ratio of -2.40 and a beta of 2.38. Sierra Oncology has a 12 month low of $1.10 and a 12 month high of $4.09.
Sierra Oncology (NASDAQ:SRRA) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.02. During the same quarter last year, the firm earned ($0.30) earnings per share. analysts predict that Sierra Oncology will post -0.86 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://baseballnewssource.com/2018/04/06/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-sierra-oncology-srra-stock-price/2030079.html.
About Sierra Oncology
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.